toxins. EHEC strains most commonly associated with human disease are lysogenized with l-like bacteriophages that encode the operons for Stxs. After Gb 3 binding, the toxins are internalized and appear to undergo "retrograde" transport to the trans-Golgi network, through Golgi stacks, to the endoplasmic reticulum [5, 6] , which may be the site of toxin translocation into the cytoplasm.
S. dysenteriae serotype 1 and EHEC are the etiologic agents of bacillary dysentery and hemorrhagic colitis, respectively. The potential for Stx-producing bacteria to cause widespread outbreaks of diarrhea was highlighted by outbreaks in the Pacific Northwest of the United States, associated with the ingestion of EHEC-contaminated hamburgers [7] , and in Sakai City, Japan, associated with EHEC-contaminated radish sprouts served in school lunches [8] . While many patients fully recover from these bloody diarrheal diseases, a fraction of patients (in particular children) go on to develop life-threatening extraintestinal complications involving the kidneys and central nervous system (CNS). The most common postdiarrheal sequela is the hemolytic uremic syndrome (HUS), oliguric or anuric acute renal failure characterized by thrombotic microangiopathy (primarily involving the glomerular endothelium), thrombocytopenia, and hemolytic anemia with schistocytes or fragmented erythrocytes noted on blood smears [9, 10] . With an increased awareness among physicians of the potential of Stx-producing bacteria to cause HUS and the early implementation of aggressive supportive therapy, including peritoneal dialysis or hemodialysis, acute renal failure as the cause of death in HUS has been reduced [11] . However, 20%-30% of HUS cases have significant encephalopathy. CNS involvement is now recognized as a major determinant of mortality in the acute phase of disease and a major factor in chronic morbidity [11, 12] .
Histopathologic studies of renal and CNS tissues from HUS patients showed that microvascular damage was a frequent finding [11, 13] . In 1988, Obrig et al. [14] showed a direct cytotoxic effect for human umbilical vein endothelial cells (HUVECs) cultured with purified Stx. It was subsequently shown that pre-or coincubation of human vascular endothelial cells, which were derived from a number of sources, with the proinflammatory cytokines tumor necrosis factor (TNF)-a or interleukin (IL)-1 markedly sensitized the cells to the cytotoxic action of Stxs [15] [16] [17] [18] [19] . Radiolabeled toxin-binding studies and thin-layer chromatography techniques showed that cytokineinduced sensitization was associated with increased expression of Gb 3 . [17, 19] Thus, cytokines produced in response to Stxs or endotoxin released through damaged gut mucosa may participate in the pathogenesis of renal and CNS vascular lesions characteristic of HUS by sensitizing the target endothelial cells to the cytotoxic action of the toxins. In this study, we examined the effects of purified Stxs on human brain microvascular endothelial cells (HBMECs) in vitro.
Materials and Methods
Toxin preparations. Purified Stxs were prepared as described elsewhere [20, 21] . In brief, recombinant E. coli DH5a strains expressing toxin operons under control of a thermoinducible promoter were sonicated, and toxins in crude lysates were purified by sequential passage through ion exchange, chromatofocusing, and immunoaffinity chromatography columns. Homogeneity of toxin preparations was determined by SDS-polyacrylamide gel electrophoresis and by Western blotting using monoclonal antibodies (MAbs) directed against Stx1 and Stx2. Trace endotoxin contaminants in the toxin preparations were removed by use of Acti-Clean Etox columns (Sterogene Bioseparations, Arcadia, CA). Fluorescein isothiocyanate (FITC)-conjugated Stx1 was prepared by dissolving 1.0 mg of Stx1 in 1.0 mL of carbonate buffer (0.25 M sodium carbonate, 0.1 M sodium chloride, pH 9.0). Fifty microliters of a 1.0-mg/mL stock solution of FITC (Sigma, St. Louis) dissolved in dimethyl sulfoxide was slowly added to the Stx1 solution. After overnight incubation at 4ЊC, unbound FITC was removed by gel filtration by use of Sephadex G-25 columns (5 Primer3 Prime, Boulder, CO). Radioiodinated Stx1 was prepared with Na 125 I and Iodogen beads (Pierce Chemical, Rockford, IL). Purified lipopolysaccharides (LPS) derived from E. coli O111:B4 were purchased from Sigma.
Cells. Primary human brain cortex microvascular endothelial cells (ACBRI 376), derived from a 16-year-old male trauma victim by the technique of Gibson et al. [22] , were purchased from Cell Systems (Kirkland, WA). In brief, human brain cortical tissue free of visible vascular tissue was minced and digested with collagenase, dispase, and DNase I. The tissue digest was filtered through a 70-mM cell strainer and resuspended with biotinylated anti-ELAM 1 MAb. Antibody-tagged cells were panned by use of streptavidincoated flasks. Cells were characterized on the basis of morphology and immunofluorescence staining: cells were 195% positive for cytoplasmic uptake of labeled acetylated low-density lipoproteins and for cytoplasmic von Willebrand's Factor/Factor VIII. Cells were negative by immunofluorescence for a panel of MAbs recognizing nonendothelial cell markers.
HBMECs were provided at passage 2 and maintained in CS-C complete medium supplemented with acidic fibroblast growth factor and 10% low-endotoxin fetal bovine serum (FBS) at 37ЊC in humidified 5% CO 2 . The cells were grown in flasks or microtiter plates coated with Attachment Factor (Cell Systems). All experiments reported here used HBMECs prior to passage 5. Three separate aliquots of HBMECs were used in all experiments. Vero cells were obtained from American Type Culture Collection (Rockville, MD) and maintained in Eagle minimum essential medium (EMEM; Life Technologies/GIBCO BRL, Grand Island, NY) plus 5% heat-inactivated FBS (Hyclone, Logan, UT) at 37ЊC in humidified 5% CO 2 . L929 murine fibroblast cells were maintained in Iscove's modified Dulbecco medium (Celox, Hopkins, MN) containing 5% FBS at 37ЊC in humidified CO 2 .
Cytotoxicity assay. Cytotoxicity was assessed by use of the 3-[4,5-dimethylthiazol-2yl]-2,5-diphenyl tetrazolium bromide (MTT) assay as previously described [21, 23] . In brief, HBMECs cultured in complete CS-C medium plus 10% FBS or Vero cells (toxinsensitive control cells) cultured in EMEM plus 5% FBS were grown in 96-well microtiter plates at and cells/well, re- 4 4 4 ϫ 10 1 ϫ 10 spectively. Serial dilutions of purified Stx1 or Stx2 (10 mg-0.1 pg/ mL) were added to confluent cell monolayers in triplicate wells. In some experiments, HBMECs were pretreated with 10 ng/mL recombinant human (rh) TNF-a (R&D Systems, Minneapolis), 10 ng/mL rhIL-1b (R&D Systems), 1.0 mg/mL LPS, 2.0 mM n-butyric acid (Sigma), or 2.0 mM 8-bromoadenosine 3 :5 -cyclic monophosphate (br-cAMP; Sigma) for 24 h before the addition of purified Stxs.
All cells were incubated with Stx1 or Stx2 for 48 h at 37ЊC in CO 2 . Twenty-five microliters of a 5.0-mg/mL stock solution of MTT (Sigma) were added to the cells, and incubation continued for an additional 2 h. Cells were lysed, and the insoluble formazan dye was extracted for 4 h at 37ЊC with 50% N,N-dimethylformamide and 20% SDS. Optical density at A 570 was measured (Dynatech MR 5000; Dynatech, Chantilly, VA). 2 ϫ 10 Stx1 (10 mg/mL) in PBS containing 0.1% NaN 3 at 4ЊC for 1 h with constant agitation. In some experiments, HBMECs were pretreated with rhTNF-a, rhIL-1b, LPS, n-butyric acid, or br-cAMP as described above. Cells were then washed 3 times with cold PBS. Binding of FITC-conjugated Stx1 to cells was detected by measuring fluorescence intensity by flow cytometry (FACScalibur; Becton Dickinson, San Jose, CA). Fluorescence intensity of 10 4 events was recorded on a logarithmic scale. Specificity of toxin binding was tested by use of competition assays, using 100-fold excess unlabeled Stx1 prior to treatment with FITC-conjugated Stx1.
Glycolipid quantitation. Total lipid extracts from HBMECs and Vero cells and purified glycolipid standards were subjected to chromatography on aluminum-backed silica thin-layer chromatography plates (Silica Gel 60; Merck, Darmstadt, Germany) with CHCl 3 -CH 3 OH-aqueous KCl (5 : 4 : 1) as described elsewhere [20] . After the separation of glycolipids, the plates were coated with 0.1% polyisobutylmethacrylate (Polyscience, Warrington, PA), air I-labeled purified Stx1 in TBS-BSA at 37ЊC for 2 h. After being washed extensively, the plates were dried, and specific toxin binding to glycolipids was visualized by use of a phosphoimager (Molecular Dynamics, Sunnyvale, CA). Relative amounts of toxin-binding glycolipids in cellular extracts were estimated by comparison with serial dilutions of purified Gb 3 separated on the same plates by use of densitometric scanning and image analysis software (IA-860 Imaging Analysis; Innotech, San Leandro, CA). Stx1-binding glycolipids were extracted and quantified in two independent experiments, and the data shown are representative of both experiments.
Cytokine assays. TNF bioactivity in cell-free supernatants was determined by the lysis of actinomycin-D-treated L929 murine fibroblast cells, as described elsewhere [21] . The sensitivity of this assay was ∼4.8 pg/mL rhTNF-a. Immunoreactive IL-1b and IL-6 were measured by use of commercially available ELISA kits (R&D Systems). The sensitivities of the IL-1b and IL-6 kits were 3.9 and 3.1 pg/mL, respectively.
RNA extraction and reverse transcription (RT). RNA was extracted by use of the acid guanidinium isothiocyanate extraction method [24] , using Ultraspec II RNA isolation reagents (Biotecx, Houston, TX). RNA purity was determined and RNA was quantified by measuring optical densities at 260 and 280 nm. RNA were reverse-transcribed by use of a commercial kit (Pharmacia Biotech, Piscataway, NJ). In brief, 5.0 mg of total RNA in 20 ml of diethyl pyrocarbonate-treated water were incubated at 65ЊC for 10 min and then chilled on ice. Eleven microliters of bulk first-strand cDNA reaction mix containing Moloney murine leukemia virus reverse transcriptase, RNAguard (Pharmacia, Piscataway, NJ), RNA/DNA-free BSA, and dNTPs were added to tubes containing heat-denatured RNA. One microliter of dithiothreitol solution (200 mM) and 0.2 mg of random hexadeoxynucleotide primer (pdN 6 , Pharmacia Biotech) were then added. The reaction proceeded for 1 h at 37ЊC and was terminated by incubation at 70ЊC for 15 min.
Polymerase chain reaction (PCR). Conditions for PCR were optimized, and the reaction was performed in a final volume of 50 ml containing different aliquots of cDNA mixed with 0.4 mM dNTP mix, 0.2 mM each primer, 2.5 U Taq polymerase (Boehringer, Indianapolis), and 5 ml of reaction buffer (200 mM Tris-HCl [pH 8.4 ], 500 mM KCl, 25 mM MgCl 2 , 1.0 mg/mL BSA). All reaction mixes were covered with a sterile wax layer to prevent evaporation during the reaction. PCR was performed for 30 cycles on a thermal cycler (Eppendorf, Fremont, CA) as follows: denaturation at 95ЊC for 1 min, primer extension at 60ЊC for 1 min, and annealing at 72ЊC for 2 min. PCR products were separated by electrophoresis in 2% agarose gels, and bands were visualized with ethidium bromide (15 mg/mL).
the following primers for human cytokines and b-actin were purchased from Perkin-Elmer Cetus (Foster City, CA) or Clontech (Palo Alto, CA): TNF-a sense, GAGTGACAAGCCTGTAG-CCCATGTAGCA, and antisense, CGAATGATCCCAAAG-TAGACCTGCCCAGACT; IL-1b sense, AAACAGATGAAG-TGCTCCTTCCAGG, and antisense, TGGAGAACACCACTT-GTTGCTCCA; IL-6 sense, ATGAACTCCTTCTCCACA-AGCGC, and antisense, GAAGAGCCCTCAGGCTGGACTG; and b-actin sense, ATGGATGATGATGATATCGCCGCG, and antisense, CTAGAAGCATTTGCGGTGGACGATGGACC.
The expected sizes of the PCR products were 444 bp for TNFa, 388 bp for IL-1b, 628 bp for IL-6, and 1126 bp for b-actin. In all experiments, the relative sizes of the PCR products were compared with HaeIII-digested fX-174 DNA.
Statistics. Student's paired t tests were performed with Microsoft Excel software (version 5.0, Microsoft, Redmond, WA).
Results

Stx1 and Stx2 cytotoxicity for HBMECs.
To determine the cytotoxic potential of Stx1 for primary HBMECs, serial dilu- tions of the toxin (10 mg/mL-0.1 pg/mL) were incubated with confluent endothelial cell monolayers, and the percentage of viable treated cells versus untreated control cells was determined at 48 h by the MTT assay. As shown in table 1, primary HBMECs were relatively refractory to the cytotoxic action of Stx1, with a 50% cytotoxic dose (CD 50 ) of 110 mg/mL. Thus, HBMECs were ∼10 7 -fold less susceptible to Stx1 than to Vero cells (CD 50 ∼1.0 pg/mL; data not shown). Several earlier studies demonstrated that proinflammatory cytokines sensitized human vascular endothelial cells derived from a number of different sources to the cytotoxic action of Stxs [15] [16] [17] [18] [19] . Preincubation of HBMECs with rhTNF-a or rhIL-1b for 24 h prior to the addition of Stx1 resulted in an ∼10
3 -fold decrease in CD 50 s. Treatment of the cells with cytokines alone had no effect on cell viability (data not shown). Pretreatment of HBMECs with n-butyric acid or br-cAMP, reagents reported to up-regulate Gb 3 expression and facilitate retrograde intracellular trafficking of the toxins [6, 18, 25] , decreased Stx1 CD 50 s to values comparable to those for cytokine pretreatment. In contrast, LPS pretreatment of HBMECs had only a modest effect on toxin sensitization.
Clinical studies have suggested that infection with Stx2-producing E. coli is a risk factor for development of HUS [26] . Stx2 appeared to be a more potent toxin than Stx1 when mouse lethality [27, 28] or human renal microvascular endothelial cell (HRMEC) cytotoxicity [29] were analyzed. Therefore, we did comparative cytotoxicity studies on HBMECs treated with purified Stx1 or Stx2 (figure 1). Differences in cytotoxicity mediated by Stx1 versus Stx2 alone were not significantly different at any toxin dilution tested ( ). When HBMECs were P ! .05 first treated with TNF-a, the degree of TNF-a-induced toxin sensitization was significantly greater for Stx1 than Stx2 only at the 10 mg/mL and 1.0 ng/mL toxin doses (denoted by the asterisks in figure 1 ). These data suggest that factors other than differences in direct HBMEC cytotoxicity or cytokine sensitization may account for the increased incidence of CNS vascular complications following infection with Stx2-producing E. coli. 
2).
Increased endothelial cell sensitivity to Stxs and modulation of toxin receptor expression by proinflammatory cytokines has been demonstrated [15] [16] [17] [18] [19] . We hypothesized, therefore, that the increased sensitivity of TNF-a-or IL-1b-treated HBMECs to Stxs may be due, at least in part, to increased binding of toxins to the cells. HBMECs were treated with TNF-a, IL-1b, or LPS for 24 h prior to incubation with FITC-conjugated Stx1 for 1 h at 4ЊC. As predicted, pretreatment of cells with proinflammatory cytokines increased Stx1 binding. Cells pretreated with TNF-a displayed a 4-fold increase in MFI ( figure 2A ; MFI, ). Cells pretreated with IL-1b displayed a 2-fold 264 ‫ע‬ 4 increase in MFI ( figure 2B; MFI, ). In accordance with 154 ‫ע‬ 14 the cytotoxicity data, pretreatment of HBMECs with LPS did not increase Stx1 binding above basal levels ( figure 2C ; MFI, 66.1). HBMECs pretreated with n-butyric acid or br-cAMP displayed enhanced Stx1 binding (MFI, and , 271 ‫ע‬ 3 227 ‫ע‬ 4 respectively).
Effects of proinflammatory cytokines on HBMEC Gb 3 content. To confirm that the increased toxin binding by cytokinetreated HBMECs detected by flow cytometry was due to increased expression of toxin-binding glycolipids, we extracted total glycolipids from pretreated (with TNF-a or IL-1b) and untreated HBMECs. Glycolipids were separated by thin-layer chromatography, and toxin-binding glycolipid species were detected by 125 I-Stx1 overlay [20] . The quantity of Gb 3 was determined by densitometric scanning comparison of dilutions of standard Gb 3 purified from porcine erythrocytes. As shown in figure 3 , untreated HBMECs contained toxin-binding glycolipids at the lower level of sensitivity of the assay (р10 pM Gb 3 / mg cells). IL-1b-treated cells contained at least 25 pM Gb 3 /mg cells, while TNF-a treatment appeared to induce at least a 4-fold increase in Gb 3 expression (42 pM Gb 3 /mg cells). In contrast to IL-1b treatment, TNF-a treatment consistently induced the expression of a toxin-binding glycolipid doublet-two bands that comigrated with and migrated slightly ahead of the Gb 3 standard.
Proinflammatory cytokine synthesis by HBMECs in response to Stx1 or LPS. The CNS sources of proinflammatory cytokines synthesized during the development of HUS and neurologic abnormalities are not known. We addressed the pos- 1b (B) , IL-6 (C), and b-actin. The positive control is a human TNF-a cDNA fragment; the negative control lacks cDNA template. PCR products were electrophoresed into 2.0% agarose gels and visualized with ethidium bromide. Molecular weight marker (MWM), HaeIII-digested fX-174 DNA molecular weight marker. Gels were electrophoresed for various times, accounting for differences in MWM band separation. MWM bands: 1353, 1078, 872, 603, and 310 bps.
sibility that HBMECs, in response to Stxs or endotoxins, may produce cytokines that act in an autocrine manner to sensitize the cells to the cytotoxic action of Stxs. HBMECs ( cell/ 6 1 ϫ 10 mL) were treated with Stx1 (200 ng/mL) or LPS (1.0 mg/mL) for 2 or 18 h. Cell-free supernatants were collected, and the presence of secreted cytokines was determined by bioassay or ELISA. The data summarized in table 2 show that incubation of HBMECs with Stx1 or LPS for 2 or 18 h induced a modest increase in the secretion of TNF-a. In contrast, neither Stx1 nor LPS induced the secretion of IL-1b. IL-6, a proinflammatory cytokine that has not been shown to modulate endothelial cell Gb 3 expression, was constitutively produced by HBMECs in culture. However, levels of soluble IL-6 were increased at 2 and 18 h after treatment with Stx1 or LPS.
Induction of HBMEC cytokine mRNA transcripts by Stx1 or LPS.
HBMECs were treated with Stx1 (200 ng/mL) or LPS (1.0 mg/mL) for 2 or 18 h. Total RNA was extracted, and RT-PCR was done using primers specific for human TNF-a, IL1b, IL-6, and b-actin. Trace PCR product for TNF-a was detected in cells treated with LPS for 2 or 18 h (figure 4A). Stx1 induced low levels of TNF-a transcripts only after prolonged (18 h) treatment. When IL-1b transcripts were analyzed, a different pattern of mRNA expression manifested (figure 4B). Stx1 treatment of HBMECs resulted in IL-1b mRNA accumulation only at the 18-h time point, while LPS treatment induced IL1b mRNA expression at both time points. Stimulation of HBMECs with Stx1 or LPS resulted in the marked induction of IL-6 mRNA at 2 and 18 h (figure 4C). 
Discussion
A great deal of information regarding the pathogenesis of HUS has accrued from studies using purified Stxs and vascular endothelial cells in vitro. These studies have highlighted the essential role of the toxins in the development of vascular lesions. Many of these studies utilized endothelial cells derived from large venous sources. Biologic and functional differences between endothelial cells derived from large vessels versus microvascular beds have become increasingly apparent (reviewed in [30, 31] ). Thus, an examination of the interaction of Stxs with microvascular endothelial cells derived from target organs is clearly warranted. However, studies using microvascular endothelial cells derived from human kidneys have produced incongruous results. Obrig et al. [32] 10 expressed ∼50-fold higher basal levels of toxin receptor in vitro, suggesting that differences in membrane Gb 3 expression may be a key component in determining the organ-specific vascular damage seen in HUS. HRMECs did not appear to be sensitized to the cytotoxic effects of Stx by pretreatment with proinflammatory cytokines or LPS.
Van Setten et al. [19] used immunomagnetic separation techniques with endothelium-specific MAbs to isolate human glomerular microvascular endothelial cells (GMVECs). Compared with HRMECs, GMVECs were relatively more resistant to Stx1 in vitro, with only 1%-6% cytotoxicity noted when cells were exposed to 10 nM/L toxin. Treatment of GMVECs with TNFa for 24 h prior to the addition of the same concentration of Stx1 rendered the cells more sensitive to the toxin, with 76%-90% killing detected, using 3 separate renal donors. The TNF-a sensitization phenomenon was accompanied by increased toxin binding and increased Gb 3 expression.
We show here that cultured HBMEC monolayers were markedly more resistant to the direct cytotoxic action of Stxs, compared with Vero cells. We estimate the HBMEC CD 50 to be ∼10 Ϫ7 M, a value in close agreement with the CD 50 for HUVECs and GMVECs (reviewed in [33] ). Exposure of HBMECs to TNF-a or IL-1b sensitized the cells to the cytotoxic action of the toxins, with the CD 50 reduced to ∼10 Ϫ10 M. Reagents reported to up-regulate toxin receptor expression and facilitate toxin intracellular transport also sensitized HBMECs to Stx1. Stx1 and Stx2 were roughly equivalent in terms of their cytotoxic potential for unstimulated HBMECs. After TNF-a treatment, both toxins appeared to be more potent cytotoxins for HBMECs. Cytokine-treated HBMECs bound more Stx1 and expressed higher levels of Gb 3 than did untreated cells.
TNF-a treatment of GMVECs was reported to increase the expression of a toxin-binding glycolipid doublet-a band that comigrated with Gb 3 and a band with slightly retarded migration compared with purified Gb 3 [19] . Treatment of HBMECs with TNF-a also resulted in the increased expression of a toxinbinding doublet-a band that comigrated with purified Gb 3 and a band that migrated slightly faster than authentic Gb 3 but slower than CDH. The precise physicochemical nature of these multiple toxin-binding glycolipid species induced by TNF-a treatment of microvascular endothelial cells remains to be determined.
LPS is not toxic for human vascular endothelial cells, and treatment of GMVECs with LPS induced only a modest increase (1.7-fold) in 125 I-Stx1 binding to the cells [19] . In accordance with these earlier studies, treatment of HBMECs with LPS resulted in a slight (10-fold) decrease in CD 50 without significantly increased toxin binding. Treatment of HBMECs with Stx1 or LPS induced the production of trace soluble TNF bioactivity, while only prolonged exposure (18 h) of HBMECs to LPS stimulated a modest increase in TNF-a transcripts. These data should be interpreted with caution. Given the power of amplification of the RT-PCR assay, we cannot rule out the possibility that TNF-a transcripts were elicited from a minor (!1%) cellular contaminant in our HBMEC cultures. In this regard, LPS has been reported to stimulate TNF-a and IL-1b production by cytokine-producing cells in the CNS (perivascular macrophages, astrocytes, or microglial cells [34, 35] ). Both Stx1 and LPS treatment increased levels of IL-1b mRNA, but elevations in soluble IL-1b were not detected in cell-free supernatants under any treatment conditions. Earlier studies have shown that a precursor form of IL-1b may be sequestered within intracellular stores [36, 37] , and release of bioactive IL1b may require the activation of the cysteine proteinase IL1b-converting enzyme or caspase-1 [38, 39] . Thus, IL-1b mRNA levels may not directly correlate with protein production or release. Both Stx1 and LPS triggered the synthesis and secretion of IL-6, a cytokine that has not been shown to modulate endothelial cell membrane Gb 3 expression.
Hutchinson et al. [40] measured Stx1 toxicity for human cerebral endothelial cells (HCECs) by using exclusion of the vital dye 5-carboxyfluorescein diacetate acetoxymethyl ester and 51 Cr release assays. They found that after 48 h of incubation with purified Stx1, HCECs were extremely sensitive to the toxin, with the CD 50 reported as !1.0 pM, a level of cytotoxicity comparable to that of Vero cells. Toxin receptor expression by HCECs was not assessed. We did not detect comparable levels of Gb 3 expression by HBMECs and Vero cells using flow cytometry and thin-layer chromatography. The reasons for the discrepancy in direct Stx1 toxicity for HCECs and HBMECs are not clear. However, it should be noted that HCECs were derived from patients of unknown age with intractable idiotypic epilepsy, whereas HBMECs were derived from a 16-year-old male who died after trauma below the shoulder. Epilepsy is a CNS disorder that may be associated with changes in neuronal glycolipids [41] and cytokine levels [42] [43] [44] . Age-associated differences may also account for differences in cytotoxicity, as brain lipid composition changes with age [45] . Finally, a number of investigators have noted extensive variability in cellular responses to Stxs. For example, Valdivieso-Garcia et al. [46] isolated porcine aortic endothelial cell lines that differed 1400-fold in sensitivity to Stx2e.
The precise reasons for variability in cytotoxic responses to Stxs is not understood, but in light of this and other studies emphasizing the requirement of proinflammatory cytokines for microvascular lesion formation, we hypothesize that variability in response to toxins may be related to differences in cytokine induction. Variability in TNF-a production in response to a standard concentration of endotoxin is known to be associated with HLA class II haplotype and polymorphism within the human TNF-a gene promoter [47] [48] [49] . TNF-a polymorphism is linked to susceptibility to inflammatory and autoimmune diseases. Thus, cytokine transcriptional activation and posttranscriptional processing events initiated by Stxs or LPS (or both) may not be identical in all patients and may contribute as a risk factor for progression to renal and CNS pathology.
